Severe SARS-Cov2 pneumonia in vaccinated patients: a multicenter cohort study.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
02 02 2023
Historique:
received: 04 04 2022
accepted: 31 01 2023
entrez: 2 2 2023
pubmed: 3 2 2023
medline: 7 2 2023
Statut: epublish

Résumé

Vaccination reduces risk of infection, hospitalization, and death due to SARS-Cov2. Vaccinated patients may however experience severe SARS-Cov2 disease. The objective was to describe clinical features of vaccinated patients requiring intensive care unit (ICU) admission due to SARS-Cov2 infection and compare them to a published cohort of unvaccinated patients. We performed a multicenter cohort study of patients with severe SARS-Cov2 disease admitted to 15 ICUs in France between January and September 2021. 100 consecutive vaccinated patients (68 (68%) men, median age 64 [57-71]) were included. Immunosuppression was reported in 38 (38%) patients. Among available serologies at ICU admission, 64% exhibited an optimal antibody level. Median SOFA score at ICU admission was 4 [4-6.3] and median PaO2/FiO2 ratio was 84 [69-128] mmHg. A total of 79 (79%) and 18 (18%) patients received high flow nasal oxygen and non-invasive mechanical ventilation, respectively. Invasive mechanical ventilation (IMV) was initiated in 48 (48%) with a median duration of 11 [5-19] days. During a median ICU length-of-stay of 8 [4-20] days, 31 (31%) patients died. Age (OR per 5-years increment 1.38 CI95% [1.02-1.85], p = 0.035), and SOFA at ICU admission (OR 1.40 CI95% [1.14-1.72] per point, p = 0.002) were independently associated with mortality. When compared to a cohort of 1316 unvaccinated patients (72% men, median age 63 [53-71]), vaccinated patients exhibited less frequently diabetes (16 [16%] vs. 351 [27%], p = 0.029) but were more frequently immunosuppressed (38 [38%] vs. 109 (8.3%), p < 0.0001), had more frequently chronic kidney disease (24 [24%] vs. 89 (6.8%), p < 0.0001), chronic heart failure (16 [16%] vs. 58 [4.4%], p < 0.0001), and chronic liver disease (3 [3%] vs. 8 [0.6%], p = 0.037) compared to unvaccinated patients. Despite similar severity, vaccinated patients required less frequently IMV at ICU day 1 and during ICU stay (23 [23%] vs. 785 [59.7%], p < 0.0001, and 48 [48%] vs. 930 [70.7%], p < 0.0001, respectively). There was no difference concerning ICU mortality (31 [31%] vs. 379 [28.8%], p = 0.64). Severe SARS-Cov2 infection after vaccination occurs mainly in patients with immunosuppression, chronic kidney, heart or liver failure. Age and disease severity are independently associated with mortality.

Identifiants

pubmed: 36732353
doi: 10.1038/s41598-023-29131-9
pii: 10.1038/s41598-023-29131-9
pmc: PMC9893202
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1902

Informations de copyright

© 2023. The Author(s).

Références

Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):125-131
pubmed: 35085222
Ann Intern Med. 2022 Mar;175(3):352-361
pubmed: 34928700
Ann Rheum Dis. 2021 Oct;80(10):1322-1329
pubmed: 34362747
Cell. 2022 Mar 17;185(6):1008-1024.e15
pubmed: 35202565
Nat Med. 2021 Jul;27(7):1147-1148
pubmed: 34239135
JAMA. 2009 Dec 2;302(21):2323-9
pubmed: 19952319
Lancet Respir Med. 2021 Dec;9(12):1439-1449
pubmed: 34599903
Cell. 2021 Mar 4;184(5):1201-1213.e14
pubmed: 33571429
Clin Infect Dis. 2022 Aug 24;75(1):e849-e856
pubmed: 34893812
Lancet Microbe. 2022 Feb;3(2):e81-e82
pubmed: 34901897
Intensive Care Med. 2022 Mar;48(3):362-365
pubmed: 35050384
Cell. 2022 Jan 6;185(1):113-130.e15
pubmed: 34921774
J Pers Med. 2021 Oct 25;11(11):
pubmed: 34834437
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Sci Immunol. 2022 Mar 25;7(69):eabo2202
pubmed: 35113647
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Ann Rheum Dis. 2022 Mar;81(3):422-432
pubmed: 34876462
Ann Rheum Dis. 2022 Feb;81(2):289-291
pubmed: 34489304
Cell. 2022 Mar 3;185(5):847-859.e11
pubmed: 35139340
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Nature. 2022 Mar;603(7901):488-492
pubmed: 35102311
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Intern Med J. 2022 Jul 16;:
pubmed: 35841294
JAMA. 1993 Dec 22-29;270(24):2957-63
pubmed: 8254858
Lancet Reg Health Eur. 2021 Dec;11:100243
pubmed: 34751263
Cell. 2022 Feb 17;185(4):603-613.e15
pubmed: 35026152
BMJ. 2021 Sep 17;374:n2244
pubmed: 34535466

Auteurs

Adrien Mirouse (A)

Département de Médecine Interne et Immunologie Cinique, Groupe Hospitalier Pitié-Salpêtrière, APHP, Paris, France. adrien.mirouse@aphp.fr.
Sorbonne Université, Paris, France. adrien.mirouse@aphp.fr.

Alice Friol (A)

Département de Médecine Interne et Immunologie Cinique, Groupe Hospitalier Pitié-Salpêtrière, APHP, Paris, France.

Anne-Sophie Moreau (AS)

Service de Réanimation Polyvalente, CHU de Lille - Hôpital Roger Salengro, Lille, France.

Boris Jung (B)

Médecine Intensive et Réanimation, PhyMedExp, Université de Montpellier, Montpellier, France.

Edouard Jullien (E)

Service de Médecine Intensive Réanimation, Hôpital Ambroise Paré, APHP, Boulogne, France.

Côme Bureau (C)

Sorbonne Université, Paris, France.
Service de Médecine Intensive Réanimation, Département R3S, Hôpital Pitié-Salpêtrière, APHP, Paris, France.

Michel Djibré (M)

Service de Médecine Intensive Réanimation, Université de Paris, Hopital Tenon, APHP, Paris, France.

Nicolas de Prost (N)

Service de Médecine Intensive Réanimation, Hôpital Henri Mondor, APHP, Créteil, France.

Lara Zafrani (L)

Service de Médecine Intensive Réanimation, Hôpital Saint-Louis, APHP, Paris, France.
Université de Paris, Paris, France.

Laurent Argaud (L)

Service de Médecine Intensive Réanimation, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.

Danielle Reuter (D)

Service de Réanimation Polyvalente, CH Sud-Francilien, Corbeil-Essonnes, France.

Laure Calvet (L)

Service de Médecine Intensive Réanimation, CHU de Clermont-Ferrand, Clermont-Ferrand, France.

Etienne de Montmollin (E)

Service de Médecine Intensive Réanimation, Hôpital Bichat, APHP, Paris, France.

Sarah Benghanem (S)

Université de Paris, Paris, France.
Service de Médecine Intensive Réanimation, Hôpital Cochin, APHP, Paris, France.

Claire Pichereau (C)

Service de Médecine Intensive Réanimation, CHI Poissy Saint Germain en Laye, Poissy, France.

Tai Pham (T)

Service de Médecine Intensive Réanimation, AP-HP, Hôpital de Bicêtre, Hôpitaux Universitaires Paris-Saclay, Le Kremlin-Bicêtre, France.
Inserm U1018, Equipe d'Epidémiologie respiratoire intégrative, CESP, Université Paris-Saclay, UVSQ, Univ. Paris-Sud, 94807, Villejuif, France.

Patrice Cacoub (P)

Département de Médecine Interne et Immunologie Cinique, Groupe Hospitalier Pitié-Salpêtrière, APHP, Paris, France.
Sorbonne Université, Paris, France.

Lucie Biard (L)

Service de Biostatistique et Information Médicale, Hôpital Saint-Louis, APHP, Paris, France.

David Saadoun (D)

Département de Médecine Interne et Immunologie Cinique, Groupe Hospitalier Pitié-Salpêtrière, APHP, Paris, France.
Sorbonne Université, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH